Oculis (NASDAQ: OCS) announced that it has filed its audited consolidated IFRS financial statements for the 2025 fiscal year and the MD&A on Form 20-F with the SEC on March 5, 2026.
Oculis (NASDAQ: OCS) announced that it has filed its audited consolidated IFRS financial statements for the 2025 fiscal year and the MD&A on Form 20-F with the SEC on March 5, 2026. Attachments include the 2025 consolidated financial statements, the MD&A and ESEF reporting files.
In the Mar 5 session, OCS gained 0.07%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Market Context
This announcement finalizes Oculis’s audited 2025 consolidated IFRS financial statements and MD&A on...
Analysis
This announcement finalizes Oculis’s audited 2025 consolidated IFRS financial statements and MD&A on Form 20-F, adding detailed transparency around the latest full-year results. In recent months, the company paired routine financial reporting with major clinical and regulatory milestones for Privosegtor and OCS-01. Investors may focus on how the new annual disclosures interact with prior financings, warrant-related resale registration under the F-3, and upcoming clinical readouts.
Key Figures
Financial year reported:2025Form type:20-F
Financial year reported
2025
Audited consolidated IFRS financial statements and MD&A
International Financial Reporting Standards (IFRS) are a set of common accounting rules used by many companies worldwide to prepare financial statements, so numbers like revenue, profit and assets are measured in the same way across borders. For investors, IFRS matters because it makes it easier to compare the financial health and performance of different companies—like using the same ruler to measure different objects—reducing surprises and helping informed investment decisions.
md&afinancial
"the audited consolidated financial statements for the financial year 2025 and the MD&A, which have now been filed"
Management’s Discussion and Analysis (MD&A) is a section of a company’s financial filing where executives explain recent results, the reasons behind changes, risks faced, and expectations for the future in plain language alongside the numbers. Investors use it like an owner’s narrative to understand the story behind the raw financial data — what drove performance, potential pitfalls, and management’s plans — helping judge whether the company’s numbers are likely to improve or worsen.
form 20-fregulatory
"have now been filed with the SEC on form 20-F, are attached."
Form 20-F is the standardized annual disclosure that non-U.S. companies must file with the U.S. securities regulator when their shares are traded in the U.S.; it contains audited financial statements, a plain-language description of the business, management discussion, governance details and key risk factors. It matters to investors because it provides a consistent, comparable company “report card” and rulebook, helping buyers assess financial health, governance and risks before investing.
The European Single Electronic Format (ESEF) is a standardized way public companies in the EU must file their annual financial reports so humans and computers can read them easily; it combines a readable document with embedded machine-readable tags that label each number and heading. For investors this matters because it makes it faster and more reliable to compare financial figures across companies—like using the same spreadsheet template for every report—improving transparency and helping spot risks or opportunities more quickly.
ZUG, Switzerland, March 05, 2026 (GLOBE NEWSWIRE) -- Following the Company‘s press release published on March 3, the audited consolidated financial statements for the financial year 2025 and the MD&A, which have now been filed with the SEC on form 20-F, are attached.
Did Oculis (OCS) file its 2025 audited consolidated financial statements with the SEC?
Yes. Oculis filed audited 2025 consolidated financial statements and MD&A on Form 20-F on March 5, 2026. According to the company, the filings include attachments for the 2025 consolidated IFRS financial statements, the MD&A and ESEF reporting files.
What attachments did Oculis (OCS) include with its March 5, 2026 Form 20-F filing?
The filing includes three attachments: the 2025 consolidated IFRS financial statements, the 2025 MD&A, and ESEF reporting files. According to the company, those documents are attached to the Form 20-F filed with the SEC.
When did Oculis (OCS) submit its 2025 consolidated financial statements to the SEC?
Oculis submitted the audited 2025 consolidated financial statements on March 5, 2026 via Form 20-F. According to the company, the Form 20-F filing contains the MD&A and ESEF reporting attachments.
Where can investors find the Oculis (OCS) 2025 MD&A and financial statements filed on March 5, 2026?
Investors can find the documents attached to Oculis's Form 20-F filed with the SEC on March 5, 2026. According to the company, the Form 20-F includes the 2025 consolidated IFRS statements, MD&A and ESEF report.
Does the Form 20-F filing for Oculis (OCS) include ESEF reporting for 2025?
Yes. The Form 20-F filed March 5, 2026 includes ESEF reporting for 2025 as an attachment. According to the company, the ESEF files accompany the audited consolidated IFRS statements and the MD&A.
